Theratechnologies picks Huss as president, CEO

Theratechnologies (TSX:TH) has named John-Michel Huss as president and CEO, succeeding Yves Rosconi, who previously informed the board of his decision to retire by the end of the year. Mr. Huss will assume the two posts in coming months. He was most recently chief of staff, office of the CEO, of Sanofi-Aventis in Paris and has [...]

Theratechnologies CEO retires; Amorfix’s steps down

Yves Rosconi, CEO and President of Theratechnologies (TSX:TH), has informed the board of his decision to retire on Dec. 31, 2010, saying he deferred his decision until the company’s lead tesamorelin product was in the final stages of the FDA approval process. A strategic committee of the board will immediately begin the formal search for [...]

FDA committee clears Theratechnologies’ tesamorelin

An FDA advisory committee recommended by a 16-to-0 unanimous vote that Theratechnologies’ (TSX:TH) tesamorelin drug should be granted marketing approval by the FDA for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy, based on a favourable benefit-risk profile. “This recommendation reinforces our belief that the tesamorelin benefit-risk profile seen in clinical trials [...]